

**METHODS OF DISEASE  
PREDICTION  
&  
PREDICTION OF TYPE 2  
DIABETES:**

**Jaakko Tuomilehto**

**Department of Public Health**

**University of Helsinki**

**Helsinki, Finland**

# Evaluation of predictions


- Calibration

- is the average of predictions correct?
- are predictions at low and high level both correct?

- Discrimination

- can one distinguish low risk individuals from high risk individuals?

## Example: predicted probabilities



# 3 types of validation

- **Apparent:** performance on sample used to develop model
- **Internal:** performance on population underlying the sample
- **External:** performance on related but slightly different population

# Apparent validity

- Easy to calculate
- Gives optimistic performance estimates

# Apparent estimates are optimistic since same data are used for:

- Definition of model structure:
  - e.g. selection and coding of variables
- Estimation of model parameters:
  - e.g. regression coefficients
- Evaluation of model performance:
  - e.g. calibration and discrimination

# Internal validity

- More difficult to calculate
- Test model in new data, **random/different** from the underlying population

# Why internal validation?

- Honest estimate of performance should be obtained, at least for a population similar to the development sample
- Internal validated performance sets an upper limit to what may be expected in other settings (external validity)



# External validity

- Moderately easy to calculate when **new data** are available
- Test model in new data, **different** from development population

# Why external validation?

- Various factors may differ from the development population, including:
  - different selection of participants
  - different definitions of variables
  - different measurement or diagnostic procedures

# Internal validation techniques

- **Split-sample:**
  - development / validation
- **Cross-validation:**
  - alternating development / validation
  - extreme:  $n-1$  develop / 1 validate  
(‘jack-knife’)
- **Bootstrap**

# Bootstrap is the preferred internal validation technique

- bootstrap sample for model development:  $n$  people drawn *with replacement*
- original sample for validation:  $n$  people
- difference: optimism
- efficiency: development and validation on  $n$  people

# Example: bootstrap results for logistic regression model

- 30-day mortality  $\sim a + b_1 \cdot \text{sex} + b_2 \cdot \text{age}$

Apparent area under the ROC curve: 0.77

Mean area of 200 bootstrap samples: 0.772

Mean area of 200 tests in original: 0.762

Optimism in apparent performance: 0.01

Optimism-corrected area: 0.76

# External validation techniques

- **Temporal validation:** same investigators, validate in recent years
- **Spatial validation (other place):** same investigators, cross-validate in centers
- **Fully external:** other investigators, other centers

# Example: external validity of logistic regression model

- 30-day mortality  $\sim a + b_1 * \text{sex} + b_2 * \text{age}$

Apparent area in 785 patients: 0.77

Tested in 20,318 other patients: 0.74

Tested by other investigators: ?

# Summary

- **Apparent validity** gives an optimistic estimate of model performance
- **Internal validity** may be estimated for instance by bootstrapping
- **External validity** should be determined in other populations



# The difference between aetiological research and disease prediction in practice

- **Aetiological research** uses maximum efforts to detect true associations between predictor parameters and outcome
- **Disease prediction** in practice uses findings from aetiological research but uses only selected, most powerful predictors in a simplified format

# **Strategies for diabetes and hyperglycaemia risk identification**

- Testing with OGTT**
- FPG testing only**
- A1C screening**
- Random capillary BG screening**
- Questionnaire comprising aetiological factors for diabetes**

# **T2D SCREENING TEST PERFORMANCE AND VALIDITY**

- **Main questions:**

- 1. What is the chance that those who have positive results are affected with diabetes/hyperglycaemia (prediabetes)?**
- 2. How well a positive test result will predict the development of future diabetes?**

# **SCREENING versus DIAGNOSIS**

- **A screening test is not intended to be diagnostic, but it should be reliable**
- **Screening procedures are easier to perform and cheaper than diagnostic tests**
- **A positive screening results requires confirmation through definitive diagnostic tests**

# Identification of high-risk individuals: FINnish Diabetes Risk Score

## The FINDRISC:

- Age
- BMI
- Waist
- Physical activity
- Nutrition (f+v)
- Hypertension
- Hyperglycaemia
- Family history

[www.diabetes.fi](http://www.diabetes.fi)

**Total Risk Score**

The risk of developing type 2 diabetes within 10 years is

Lower than 7	Low: estimated 1 in 100 will develop disease
7-11	Slightly elevated: estimated 1 in 25 will develop disease
12-14	Moderate: estimated 1 in 6 will develop disease
15-20	High: estimated 1 in 3 will develop disease
Higher than 20	Very high: estimated 1 in 2 will develop disease

**FINnish Diabetes Association**

**Assessment form**

How often do you eat vegetables, fruit or berries?  
 Never 0-1  
 Sometimes 2-3  
 Most of the time 4-5

How often do you eat whole grains (e.g. whole wheat bread, rye, oatmeal, barley, brown rice, etc.)?  
 No 0-1  
 Yes 2-3

How often do you have food to lose weight (diet, exercise, etc.)?  
 Never 0-1  
 Yes 2-3

How many of the members of your immediate family or other relatives have diagnosed type 2 diabetes (age 50 or older)?  
 No 0-1  
 Yes 2-3

Do you regularly walk or jog for exercise? (at least 30 minutes, 3-4 times a week)  
 No 0-1  
 Yes 2-3

Do you smoke tobacco (at least 10 cigarettes a day)?  
 No 0-1  
 Yes 2-3

**Waist Circumference**

The risk of developing type 2 diabetes within 10 years is

Lower than 7	Low: estimated 1 in 100 will develop disease
7-11	Slightly elevated: estimated 1 in 25 will develop disease
12-14	Moderate: estimated 1 in 6 will develop disease
Higher than 20	Very high: estimated 1 in 2 will develop disease

**Illustrations:** Two figures showing waist circumference measurement. The left figure shows a normal waist, and the right figure shows an enlarged waist.

**Footnote:** Lindström and Tuomilehto. Diabetes Care 2003;26:725-31.

# **FINnish Diabetes RIsk SCore (FINDRISC)**

- **Developed based on the real prospective data (baseline examination in 1987 and 10-year follow-up)**
- **Validated in cross-sectional and independent prospective data sets**
- **Scoring weights for the individual items derived from the empirical data: multivariate logistic model**

# **FINDRISC: The aim**

**To develop a tool that:**

- is simple, inexpensive and reliable way to identify people at high risk of T2D**
- can be applied in the general population by lay people**
- does not require blood drawing or other measurements that require trained personnel or special equipments**

**Risk model development:  
FINRISK87 - SURVEY**

Excluded if

- age < 35 yrs.
- DM medication
- missing variables

**4435 subjects with  
baseline Risk Score**

**10 years follow-up  
(drug register)**

**182 DM cases  
identified**

**Risk model validation:  
FINRISK92 - SURVEY**

Excluded if

- age < 35 yrs.
- DM medication
- missing variables

**4586 subjects with  
baseline Risk Score**

**5 years follow-up  
(drug register)**


**67 DM cases  
identified**



# Analysis of Maximum Likelihood Estimates


<b>Variable</b>	<b>Parameter Estimate</b>	<b>p</b>	<b>Odds Ratio</b>	<b>RISK SCORE</b>
INTERCEPT	<b>-5.671</b>	0.0001		
BMI_D1	<b>0.011</b>	0.9777	1.01	<b>1</b>
BMI_D2	<b>0.928</b>	0.0299	2.53	<b>3</b>
WAIST_D1	<b>1.037</b>	0.0022	2.82	<b>3</b>
WAIST_D2	<b>1.445</b>	0.0001	4.24	<b>4</b>
AGE_D1	<b>0.654</b>	0.0150	1.92	<b>2</b>
AGE_D2	<b>0.945</b>	0.0003	2.57	<b>3</b>
GLUCOSE	<b>2.261</b>	0.0001	9.59	<b>5</b>
BP_MED	<b>0.711</b>	0.0001	2.04	<b>2</b>
FRUIT+VEGET	<b>0.165</b>	0.3248	1.18	<b>1</b>
EXERCISE	<b>0.264</b>	0.1964	1.30	<b>2</b>

# Diabetes incidence during 10-year follow-up by baseline FINDRISC value



# ROC - curve for FINDRISC (Score 0-20)

## Finrisk87 - Prospective 10-year follow-up



Cutpoint: score  $\geq 10$

sensitivity = 0.73

specificity = 0.83

positive predictive  
value = 0.16

negative predictive  
value = 0.99

AUC =  
Area Under the Curve

## **Sensitivity:**

The probability that the people with disease will be test positive.

## **Specificity:**

The probability that the test will be negative if the disease is truly absent.

# ROC curve


A receiver operating characteristic curve, or ROC curve, is a graphical plot that illustrates the diagnostic ability of a binary classifier system.

The ROC curve is created by plotting the true positive rate (TPR) against the false positive rate (FPR) at various threshold settings. The true-positive rate is also known as sensitivity, recall or *probability of detection* in machine learning.

The false-positive rate is also known as the **fall-out** or *probability of false alarm* and can be calculated as  $(1 - \text{specificity})$ .


# ROC - curve for DM Risk Score validation (Score 0-20):

## Finrisk92 - Prospective data




**Score  $\geq 9 \rightarrow$**   
**sensitivity= 0.81**  
**specificity= 0.76**  
**Pos. predictive value= 0.05**  
**AUC = 0.87**

# Prevalence of abnormal glucose tolerance



Unrecognized type 2 diabetes



IGT, IFG or unrecognized T2DM

# FINDRISC predicts the risk of myocardial infarction

One point increase in score =

- 15% risk increase in men
- 19% risk increase in in women

	Men		Women	
	Hazard ratio	95% CI	Hazard ratio	95 % CI
<b>Model 1</b>	<b>1.15</b>	<b>1.12–1.19</b>	<b>1.19</b>	<b>1.14–1.24</b>
<b>Model 2</b>	<b>1.15</b>	<b>1.11–1.19</b>	<b>1.19</b>	<b>1.14–1.24</b>
<b>Model 3</b>	<b>1.04</b>	<b>1.00–1.08</b>	<b>1.06</b>	<b>1.00–1.12</b>


Model 1: Diabetes Risk Score alone

Model 2: Model 1 + adjusted for smoking

Model 3: Model 2 + SBP + total and HDL-cholesterol




# Fatty Liver by FINDRISC in Brazil




# The Danish Risk Score

Variable	$\beta$ -coeff	OR	95% CI	Risk score
Age (45 vs. 30-40)	0.6926	2.0	(1.0-4.1)	7
Age (50 vs. 30-40)	1.3111	3.7	(2.0-7.0)	13
Age (55-60 vs. 30-40)	1.8475	6.3	(3.5-11.5)	18
Gender (m vs. f)	0.3970	1.5	(1.0-2.2)	4
BMI 25-29 vs. < 25	0.7401	2.1	(1.3-3.5)	7
BMI $\geq$ 30 vs. <25	1.4672	4.4	(2.6-7.3)	15
Known hypertension (y vs. n)	0.9832	2.7	(1.8-4.0)	10
PAL (inactive vs. active)	0.6488	1.9	(1.0-3.5)	6
Parent diabetic: (y vs. n)	0.6835	2.0	(1.3-3.0)	7


# Performance of the Danish Risk Score



# Association of quintiles of risk score with clinical incidence of diabetes – Epic-Norfolk study



# ROC curve for the detection of clinically incident diabetes using the risk score – Epic-Norfolk study





- The Leicester South Asian Score can be used to identify those at high risk of IGR and T2DM in UK multi-ethnic populations
- The score is simple (7 questions), non invasive and inexpensive
- This score may be used to increase the uptake to screening

# A risk score for predicting incident diabetes in a Thai population in a 10-year follow-up

Risk factor	Coefficient	Diabetes risk score
Age (years)		
34–39		0
40–44	−0.07	0
45–49	0.27	1
≥50	0.60	2
Sex		
Women		0
Men	0.44	2
BMI ( $\text{kg}/\text{m}^2$ )		
<23		0
≥23 but <27.5	0.60	3
≥27.5	1.24	5
Waist circumference (cm)		
<90 in men, <80 in women		0
≥90 in men, ≥80 in women	0.50	2
Hypertension		
No		0
Yes	0.64	2
History of diabetes in parent or sibling		
No		0
Yes	1.00	4

- The ability to predict diabetes risk correctly ( $\text{AUC}_{\text{roc}}$ : 78%)
- Adding fasting glucose into the model did not improve the prediction

# Indian Diabetes risk score

Variables	Risk score
Age (30 – 44) yrs	10
Age (45 – 59) yrs	18
Age (>59) yrs	19
Family history of diabetes	7
Body mass index ( $\geq 25$ ) kg/m <sup>2</sup>	7
Waist (M = >85 , W = >80 cm)	5
Sedentary physical activity	4
<b>Maximum Score</b>	<b>42</b>

A person with a score  $\geq 21$  has high probability of having Diabetes undetected



# OMANI DIABETES RISK SCORE

## 1. Age

0 p. 20 - 39 years

7 p. 40 - 59 years

9 p. 60 + years

## 2. Body mass index

0 p. < 25 kg/m<sup>2</sup>

2 p. 25 - 29 kg/m<sup>2</sup>

3 p. ≥ 30 kg/m<sup>2</sup>

## 3. Waist circumference

MEN

0 p. < 94 cm

2 p. 94 + cm

WOMEN

< 80 cm

80 + cm

## 4. Family history of diabetes

0 p. No

8 p. Yes

## 5. Current hypertension status

0 p. No

3 p. Yes

### • The area under the curve:

1991: 0.83 (95%CI 0.82 to 0.84);

2001: 0.76 (95%CI 0.74 to 0.79).


### • The cut-point of Diabetes Risk Score >10 in the 1991 cohort :

- sensitivity 78.6% (74.6% - 82.1%)

- specificity 73.4% (72.0% - 74.7%)

**Total score points:  
0-25**

# European risk score for prediction of CVD events: SCORE




# Diabetes Risk Scoring system in Indian men in Mauritius




# DETECT -2: Prospective analysis to identify diabetes

## ROC Curve



**Extended model** (area under the ROC-curve 0.781 [95% CI 0.763-0.800])  
**Re-estimated Finnish model** (area under the ROC-curve 0.753 [95% CI 0.734-0.773])  
**Finnish diabetes risk score** (area under the ROC-curve 0.750 [95% CI 0.730-0.770])

# DPS: Diabetes incidence in the intervention vs. control group by baseline FINDRISC



**Will determining  
the diabetes risk  
help to prevent  
the development of T2D  
in high-risk individuals?**

# FINDRISC in the Finnish Diabetes Prevention Study (DPS) population


## The DPS control group

- age 40-64, BMI >25, IGT
- **annual laboratory visit**
- n=236 with baseline  
FINDRISC
- median follow-up 3 years

## The DPS intervention group

- age 40-64, BMI >25, IGT
- **lifestyle intervention**
- n=233 with baseline  
FINDRISC
- median follow-up 3 years


# Diabetes rate (cases/100 person-years) by baseline FINDRISC value: the DPS **control group**




**Control Group**



# Diabetes rate (cases/100 person-years) by baseline FINDRISC value: the DPS **intervention group**



**Control Group**




**Intervention Group**

# Sensitivity

If the cut off point of this test is set low then it will be sensitive (all people with disease will be test positive) but there will also be a number of false positives


**For ex. in the OGTT  
2-h PG > 7.8 mmol/l**



# Specificity

- **The probability that the test will be negative if the disease is truly absent.**
- **A specific test has a high likelihood of false negatives.**

# Hypoglycemia



**For ex. HbA1c >6.5%**

# Performance of FINDRISC in identifying unrecognized T2DM

among 45-74-year old men and women (Finrisk-02, n=2966)

	Sensitivity	PPV	NPV	% of study sample
<b>Cutoff value = 11</b>				
Men	66%	22%	94%	<b>35%</b>
Women	70%	11%	96%	<b>41%</b>
<b>Cutoff value = 13</b>				
Men	45%	25%	92%	<b>21%</b>
Women	55%	14%	96%	<b>27%</b>
<b>Cutoff value = 15</b>				
Men	30%	30%	91%	<b>12%</b>
Women	38%	16%	95%	<b>16%</b>

Saaristo et al.  
Diabetes Vasc  
Dis Res 2005;  
2:67-72

# Performance of the FINDRISC to identify abnormal glucose tolerance in other populations

	Cutoff point	Sensitivity	Specificity	Ref.
<b>The IGLOO Study, Italy</b>				
n=1377, age 55-77	$\geq 9$	77% (DM/IGT)	45%	Franciosi et al. Diabetes Care 2005; 28:1187-1194
<b>Krakow, Poland (DM/IGT)</b>				
n=12496	$\geq 9$	82% (DM/IGT)	70%	Szurkowska et al. Przegląd Lekarski 2006; 63 (Suppl. 4):P42
<b>The KORA Survey 2000, Germany (DM)</b>				
n=1353, age 55-74	$\geq 9$	82% (DM)	43%	Rathmann et al. 2005; 165:436-441

# FINDRISC has been translated to >30 languages and is used around the world either in original or adapted version, and used in over 200 publications

The performance of the Finnish Diabetes Risk Score, a modified Finnish Diabetes Risk Score and a simplified Finnish Diabetes Risk Score in a community-based cross-sectional screening of undiagnosed Type 2 diabetes in the Philippines.

## CANRISK



### Performance of FINDRISC



Age Group	Prevalence	Findrisc	Canrisk
18-24	0%	0.00	0.00
18-24	10%	0.05	0.05
18-24	20%	0.10	0.10
18-24	30%	0.15	0.15
18-24	40%	0.20	0.20
18-24	50%	0.25	0.25
18-24	60%	0.30	0.30
18-24	70%	0.35	0.35
18-24	80%	0.40	0.40
18-24	90%	0.45	0.45
18-24	100%	0.50	0.50

## ¿Cómo se usa?

El FINDRISC es un cuestionario de auto-evaluación que permite identificar a las personas con mayor riesgo de desarrollar diabetes tipo 2. Se recomienda utilizarlo en personas de 30 años de edad o más que no estén tomando medicamentos para controlar la diabetes.



El FINDRISC es un cuestionario de auto-evaluación que permite identificar a las personas con mayor riesgo de desarrollar diabetes tipo 2. Se recomienda utilizarlo en personas de 30 años de edad o más que no estén tomando medicamentos para controlar la diabetes.

Age Group	Prevalence	Findrisc	Canrisk
18-24	0%	0.00	0.00
18-24	10%	0.05	0.05
18-24	20%	0.10	0.10
18-24	30%	0.15	0.15
18-24	40%	0.20	0.20
18-24	50%	0.25	0.25
18-24	60%	0.30	0.30
18-24	70%	0.35	0.35
18-24	80%	0.40	0.40
18-24	90%	0.45	0.45
18-24	100%	0.50	0.50

## Diagnostic accuracy of the Finnish Diabetes Risk Score (FINDRISC) for undiagnosed T2DM in Peruvian population

Antonio Bernabe-Ortiz<sup>1,2</sup>, Julia Ford<sup>3</sup>, Juan Jaime Miranda<sup>1,2</sup>, Luis Smith<sup>4</sup>

Age Group	Prevalence	Findrisc	Canrisk
18-24	0%	0.00	0.00
18-24	10%	0.05	0.05
18-24	20%	0.10	0.10
18-24	30%	0.15	0.15
18-24	40%	0.20	0.20
18-24	50%	0.25	0.25
18-24	60%	0.30	0.30
18-24	70%	0.35	0.35
18-24	80%	0.40	0.40
18-24	90%	0.45	0.45
18-24	100%	0.50	0.50

# The most common diabetes risk score components

- **Age**
- **BMI**
- **Waist circumference**
- **Family history of diabetes**
- **Sex**
- **Fasting glucose**
- **Ethnicity**
- **Blood pressure**
- **Triglycerides**
- **Physical activity**
- + HDL-cholesterol, diet (fruit and vegetables, red meat, whole grain bread, coffee, alcohol), 2h glucose, smoking, height, social deprivation, LDL-cholesterol, steroid medication, delivery of macrosomic infant, education



# CONCLUSION - ADVICE

**Never use blood glucose testing  
in a non-diabetic person  
without determining  
her/his diabetes risk**

# CONCLUSIONS

- Diabetes risk scores have been developed/validated in several populations
- They work well in predicting future development of T2D, but may be to some extent population-specific
- Risk scores can also be used as primary screening tool to detect undiagnosed T2D
- The parameters included in various models and scores are more or less the same, but the cut-points and score weights (beta-coefficients) are different
- A universal diabetes risk score may not be possible, but it is possible to implement diabetes risk scores in all populations
- There is good evidence that people at high risk identified by risk score benefit from healthy lifestyle advice